Skip to main content
. 2016 Oct 17;46(5):221–225. doi: 10.4274/tjo.82542

Table 2. Clinical findings in eyes treated with intravitreal bevacizumab and eyes not treated with intravitreal bevacizumab.

graphic file with name TJO-46-221-g2.jpg